The TROPION-Lung01 trial is a phase 3 trial of Datopotamab Deruxtecan (DatoDXD) vs docetaxel in the pretreated setting for the treatment of NSCLC. The clinical trial sponsors AstraZeneca and Daiichi Sankyo chose a fairly aggressive PR strategy as they rolled out their media communications at #ASCO24 , for a data presentation at #WCLC24. The data may potentially lead to an FDA approval in a subset of patients, as the broad population of patients in the trial did not achieve a survival benefit. So what do KOLs think of the data?
The ASCO discusion whihc only included the data from the Press Release was fairly critical of the trial sponsors:
However, there is a great need for treatments in the non-squamous NSCLC population, and Dr. Patrick Forde asked a good questions regarding the potential for an FDA approval from these data (from the ASCO24 discussion).
At #WSCLC24, @ASCO shared a tweet highlighting a quote from presenter Dr. Jacob Sands regarding the potential for DatoDXD in the non-squamous population.
For more information from Dr. Sands, please see the podcast below:
However, KOL Dr. Riyaz Shah, an oncologist from the UK was not impressed with the data.
However, there was some excitement from the KOLs regaridng the potential for an AI based biomarker to support the patient selection of DataDXD in this patient population.
Dr Tom John expressed some positivity regarding this new technology for treatment selection of with DATADXD. Could this be a breakthrough?
Dr. Young Kwon Chae is impressed by the potential for an AI based biomarker.
Will the FDA approve DatoDXD in this difficult to treat patient population based on subset data? Will Artificial Intelligence based biomarker save the day? Jacob Plieth asked the question:
|
|
|
|---|---|
|
|
|